MLČOCH, Tomáš, Barbora DECKER, Eva ORNSTOVÁ, Kateřina CHADIMOVÁ, Jana BARTÁKOVÁ a Tomáš DOLEŽAL. Cost-effectiveness analysis of parenteral methotrexate for the treatment of Crohn’s disease in the Czech Republic. In ISPOR Europe 2018, Barcelona. 2018. ISSN 1098-3015. Dostupné z: https://dx.doi.org/10.1016/j.jval.2018.09.865. |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1852607, author = {Mlčoch, Tomáš and Decker, Barbora and Ornstová, Eva and Chadimová, Kateřina and Bartáková, Jana and Doležal, Tomáš}, booktitle = {ISPOR Europe 2018, Barcelona}, doi = {http://dx.doi.org/10.1016/j.jval.2018.09.865}, title = {Cost-effectiveness analysis of parenteral methotrexate for the treatment of Crohn’s disease in the Czech Republic}, url = {https://www.valueinhealthjournal.com/article/S1098-3015(18)34167-6/fulltext}, year = {2018} }
TY - CONF ID - 1852607 AU - Mlčoch, Tomáš - Decker, Barbora - Ornstová, Eva - Chadimová, Kateřina - Bartáková, Jana - Doležal, Tomáš PY - 2018 TI - Cost-effectiveness analysis of parenteral methotrexate for the treatment of Crohn’s disease in the Czech Republic UR - https://www.valueinhealthjournal.com/article/S1098-3015(18)34167-6/fulltext N2 - Over a three-year time horizon, MTX yields additional 0.06 QALYs (1.92 vs. 1.86) at the additional total cost of €761 (€2263 vs. €1503) compared with hdCS, with the incremental cost-effectiveness ratio of €13,077/QALY. PSA showed that probability of MTX to be cost-effective was 99.89% at the WTP. OWSA and SA confirmed the robustness of the base-case result with all one-way changes and scenarios deeply below WTP. ER -
MLČOCH, Tomáš, Barbora DECKER, Eva ORNSTOVÁ, Kateřina CHADIMOVÁ, Jana BARTÁKOVÁ a Tomáš DOLEŽAL. Cost-effectiveness analysis of parenteral methotrexate for the treatment of Crohn’s disease in the Czech Republic. In \textit{ISPOR Europe 2018, Barcelona}. 2018. ISSN~1098-3015. Dostupné z: https://dx.doi.org/10.1016/j.jval.2018.09.865.
|